Randomized comparative study on efficacy and safety of reduced-dose steroid combined with tacrolimus vs conventional-dose steroid in late- or elderly-onset myasthenia gravis patients

Randomized comparative study on efficacy and safety of reduced-dose steroid combined with tacrolimus vs conventional-dose steroid in late- or elderly-onset myasthenia gravis patients - Steroid combined with tacrolimus for late- or elderly-onset patients of myasthenia gravis (STEP-MG)

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007671

Enrollment

Registered

2012-04-09

Start date

2012-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myasthenia gravis

Interventions

Administration of prednisolone 35 mg/day with tacrolimus 3mg a day Administration of prednisolone 50 mg/day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: late- or elderly-onset myasthenia gravis patients

Exclusion criteria

Exclusion criteria: Patients disqualified by doctor in attendance with any reason

Design outcomes

Primary

Measure	Time frame
Percentage of the patients taking prednisolone less than 5mg/day and maintaining with Minimal Manifestations after 2 years	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026